Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents (CORRECTION)
Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents (CORRECTION)
This study will assess the safety and efficacy of once daily dosing of vadadustat for the treatment of pediatric participants with anemia of chronic kidney disease (CKD) naive to erythropoiesis-stimulating agent (ESA) treatment.
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 71 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Once Daily Oral Vadadustat for The Treatment of Pediatric Subjects With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-stimulating Agents
Estimated Study Start Date: February 2022
Estimated Primary Completion Date: July 2026
Estimated Study Completion Date: October 2026
Arm:
- Experimental: Vadadustat
| Category | Value |
|---|---|
| Study type(s) | Interventional |
| Estimated enrolment | 71 |
| Estimated Study start date | 01 February 2022 |
| Estimated Study Completion Date | 01 October 2026 |